5 Best Biotech Penny Stocks To Buy Now

Number of Hedge Fund Holders: 7

Share Price (as of June 17): $1.04

Atossa Therapeutics, Inc. (NASDAQ:ATOS) is based in Seattle, Washington, and focuses on the development of medicines to treat cancer and infectious diseases. Its lead candidate is Endoxifen, which is the main ingredient of FDA-approved drug Tamoxifen which has been used to treat breast cancer for decades. Atossa Therapeutics, Inc. (NASDAQ:ATOS) aims to deliver Endoxifen directly to the body and bypass liver metabolism, a process which potentially yields quicker and better results than the traditional Tamoxifen drug. The company is also working on an inhalation therapy named AT-H201, which is intended for use by moderate to severe hospitalized patients of COVID-19, as well as for patients who suffer from post-Covid lung disease.

In March, Atossa Therapeutics, Inc. (NASDAQ:ATOS) was issued a new patent from the U.S. Patent and Trademark office, further strengthening its intellectual property surrounding the Endoxifen drug. For the first quarter, the company reported earnings per share of -$0.04, beating market forecasts by $0.02. 

With a $4.82 million stake, D E Shaw was the most prominent shareholder of Atossa Therapeutics, Inc. (NASDAQ:ATOS) in the first quarter of 2022. In total, 7 hedge funds were long on the company shares, with aggregate positions worth $10.56 million.